← Russell 3000 cross-section

OSG OCTAVE SPECIALTY GROUP INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Financials

Scale

Market cap
$206m
Revenue TTM
$194m
Net income TTM
$-161m
Free cash flow
Composite score
Sector rank
#2856

Valuation

P / E
EV / EBITDA
EV / sales
1.4
FCF yield
Earnings yield vs 10-yr
-82.78pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-82.7%
EBITDA margin
ROE
-23.0%
ROIC
Revenue growth
51.6%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For all periods leading up to the sale, AAC's results of operations and OSG's loss on sale are reported within Net income (loss) to shareholders from discontinued operations after tax on the Consolidated Statements of Income (Loss). Th e increase was p rimarily due to strong ID organic growth as well as the acquisition of ArmadaCare in October of 2025. Program fees for three and six months ended June 30, 2026 are slightly lower versus the three and six months ended June 30, 2025, due to the shift in net retention levels partially offset by growth in certain programs. …OCTAVE SPECIALTY GROUP INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →